A detailed history of Commonwealth Equity Services, LLC transactions in Bluebird Bio, Inc. stock. As of the latest transaction made, Commonwealth Equity Services, LLC holds 19,326 shares of BLUE stock, worth $6,764. This represents 0.0% of its overall portfolio holdings.

Number of Shares
19,326
Previous 28,497 32.18%
Holding current value
$6,764
Previous $28,000 64.29%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$0.47 - $1.35 $4,310 - $12,380
-9,171 Reduced 32.18%
19,326 $10,000
Q1 2024

Apr 29, 2024

BUY
$0.91 - $1.75 $13,104 - $25,200
14,400 Added 102.15%
28,497 $36,000
Q4 2023

Feb 06, 2024

BUY
$1.32 - $4.83 $18,608 - $68,088
14,097 New
14,097 $19,000
Q4 2022

Feb 07, 2023

BUY
$5.77 - $8.49 $79,320 - $116,712
13,747 New
13,747 $95,000
Q1 2020

May 11, 2020

SELL
$26.16 - $63.5 $93,260 - $226,377
-3,565 Closed
0 $0
Q4 2019

Feb 05, 2020

SELL
$46.96 - $61.67 $27,377 - $35,953
-583 Reduced 14.05%
3,565 $312,000
Q3 2019

Oct 30, 2019

BUY
$59.47 - $93.1 $21,111 - $33,050
355 Added 9.36%
4,148 $380,000
Q2 2019

Jul 19, 2019

BUY
$75.84 - $105.21 $17,443 - $24,198
230 Added 6.46%
3,793 $482,000
Q1 2019

May 13, 2019

SELL
$64.44 - $104.11 $20,814 - $33,627
-323 Reduced 8.31%
3,563 $560,000
Q4 2018

Feb 11, 2019

BUY
$59.1 - $93.26 $84,513 - $133,361
1,430 Added 58.22%
3,886 $385,000
Q3 2018

Nov 06, 2018

BUY
$88.86 - $117.49 $20,437 - $27,022
230 Added 10.33%
2,456 $358,000
Q2 2018

Jul 31, 2018

BUY
$99.64 - $127.59 $28,895 - $37,001
290 Added 14.98%
2,226 $349,000
Q1 2018

May 14, 2018

BUY
$105.8 - $150.94 $40,521 - $57,810
383 Added 24.66%
1,936 $330,000
Q4 2017

Feb 12, 2018

BUY
$81.25 - $130.7 $126,181 - $202,977
1,553
1,553 $277,000

Others Institutions Holding BLUE

About bluebird bio, Inc.


  • Ticker BLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,121,800
  • Market Cap $27M
  • Description
  • bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...
More about BLUE
Track This Portfolio

Track Commonwealth Equity Services, LLC Portfolio

Follow Commonwealth Equity Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Commonwealth Equity Services, LLC with notifications on news.